rs116840795
Variant summary
Our verdict is Likely pathogenic. The variant received 7 ACMG points: 7P and 0B. PM1PP2PP3_Strong
The NM_033337.3(CAV3):c.169G>A(p.Val57Met) variant causes a missense change. The variant allele was found at a frequency of 0.00000867 in 1,613,994 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. V57G) has been classified as Uncertain significance.
Frequency
Consequence
NM_033337.3 missense
Scores
Clinical Significance
Conservation
Publications
Genome browser will be placed here
ACMG classification
Our verdict: Likely_pathogenic. The variant received 7 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| CAV3 | NM_033337.3 | c.169G>A | p.Val57Met | missense_variant | Exon 2 of 2 | ENST00000343849.3 | NP_203123.1 | |
| CAV3 | NM_001234.5 | c.169G>A | p.Val57Met | missense_variant | Exon 2 of 3 | NP_001225.1 | ||
| OXTR | XR_007095681.1 | n.1885-2978C>T | intron_variant | Intron 4 of 4 |
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| CAV3 | ENST00000343849.3 | c.169G>A | p.Val57Met | missense_variant | Exon 2 of 2 | 1 | NM_033337.3 | ENSP00000341940.2 | ||
| CAV3 | ENST00000397368.2 | c.169G>A | p.Val57Met | missense_variant | Exon 2 of 3 | 1 | ENSP00000380525.2 | |||
| CAV3 | ENST00000472766.1 | n.155+11590G>A | intron_variant | Intron 1 of 2 | 2 |
Frequencies
GnomAD3 genomes AF: 0.00000657 AC: 1AN: 152156Hom.: 0 Cov.: 32 show subpopulations
GnomAD2 exomes AF: 0.0000119 AC: 3AN: 251334 AF XY: 0.0000147 show subpopulations
GnomAD4 exome AF: 0.00000889 AC: 13AN: 1461838Hom.: 0 Cov.: 32 AF XY: 0.00000688 AC XY: 5AN XY: 727212 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.00000657 AC: 1AN: 152156Hom.: 0 Cov.: 32 AF XY: 0.0000135 AC XY: 1AN XY: 74332 show subpopulations
ClinVar
Submissions by phenotype
not provided Uncertain:2Other:1
Identified in a patient with persistently elevated CK levels and reduced CAV3 in sarcolemma of muscle fibers on muscle biopsy; however, he was not otherwise symptomatic for muscular disorder, had a normal ECG, and his mother and brother who were also heterozygous for the variant had persistently elevated CK levels with no muscular symptoms (Alias et al., 2004); Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 15564037, 34426522, 27772553, 15099591, 22581547)
Long QT syndrome Pathogenic:1
Studies have shown that this missense change alters CAV3 gene expression (PMID: 15099591). This sequence change replaces valine, which is neutral and non-polar, with methionine, which is neutral and non-polar, at codon 57 of the CAV3 protein (p.Val57Met). This variant is present in population databases (rs116840795, gnomAD 0.006%). This missense change has been observed in individuals with autosomal dominant CAV3-related conditions (PMID: 15099591, 22581547, 26404900, 27772553; Invitae). ClinVar contains an entry for this variant (Variation ID: 31708). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic.
not specified Uncertain:1
Variant summary: CAV3 c.169G>A (p.Val57Met) results in a conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 1.2e-05 in 251334 control chromosomes. c.169G>A has been reported in the literature in heterozygous individuals affected with Rippling Muscle Disease 2 (Alias_2004, Macias_2016, Magri_2015, Milone_2012). These data indicate that the variant may be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 15099591, 27772553, 26404900, 22581547). ClinVar contains an entry for this variant (Variation ID: 31708). Based on the evidence outlined above, the variant was classified as VUS-possibly pathogenic.
Cardiomyopathy Uncertain:1
Cardiovascular phenotype Uncertain:1
The c.169G>A (p.V57M) alteration is located in exon 2 (coding exon 2) of the CAV3 gene. This alteration results from a G to A substitution at nucleotide position 169, causing the valine (V) at amino acid position 57 to be replaced by a methionine (M). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear.
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at